This activity has been designed to meet the educational needs of physicians, advanced practice clinicians, nursing professionals, pharmacists, and other members of the healthcare team who manage patients with multiple sclerosis (MS).
Upon completion of this educational activity, the participant should be able to:
- Explain basic mechanisms in approved MS DMTs
- Analyze rationale for use of certain mechanisms for MS disease management
- Apply knowledge of therapeutic mechanisms to expand education of patients with MS and other healthcare professionals
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Delaware Media Group. The CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurse Credentialing Center (ANCC) to provide continuing medical education for the healthcare team.
The CMSC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The CMSC designates this enduring material for a maximum of 1.25 Continuing Nursing Education Credits (1.25 of these credits are in the area of pharmacology).
The Consortium of Multiple Sclerosis Centers (CMSC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education and will award 1.25 contact hours (.125 CEUs) to pharmacists who (1) complete the activity, (2) submit a passing posttest, and (3) complete the evaluation form. The Universal Activity Number (UAN) for this activity is JA4008165-9999-19-001-H01-P. This is a knowledge-based activity.
Upon successful completion of the activity, your CE credits will be submitted electronically to the NABP CPE Monitor service. For information about CPE Monitor, visit https://nabp.pharmacy/cpe-monitor-service/
Paper certificates are not valid for pharmacy credit.
Corey C. Ford, MD, PhD
Dr. Ford has disclosed the following financial relationships:
Sources of Funding for Research: Actelion, Adamas, Alkermes, Biogen, Genentech, Genzyme, Mallinckrodt, Medday, Novartis, Roche, Sanofi Aventis, and Teva Pharmaceuticals; Consulting Agreements: Teva Pharmaceuticals
Andrew D. Goodman, MD
Dr. Goodman has disclosed the following financial relationships:
Sources of Funding for Research: Adamas, Atara, Biogen, Roche, Sanofi Genzyme, Sun Pharma, Teva Pharmaceuticals; Consulting Agreements: Abide, Adamas, EMD Serono, Sun Pharma
Laurie Scudder, DNP, NP
Laurie Scudder has disclosed no relevant financial relationships.
Planners and Managers
The following planners and managers have disclosed no relevant financial relationships: Joseph J. D’Onofrio, Frank Marino, Katherine Wandersee.
Commercial Support Acknowledgement
This continuing education publication is supported by an educational grant from Genentech.
Code: CMSC-DELMED 2019/1
Release Date: February 28, 2019
Credit for this program expires February 29, 2020